Deep Dive Into WAVE Life Sciences Stock: Analyst Perspectives (4 Ratings)
Portfolio Pulse from Benzinga Insights
WAVE Life Sciences (NASDAQ:WVE) has been analyzed by four analysts, revealing a mix of bullish and somewhat bullish ratings. The average 12-month price target is $14.25, with a high of $19.00 and a low of $11.00. Recent evaluations show a decline in the average price target by 16.18%. Financial indicators reveal challenges, including a decline in revenue growth, negative net margin, and below-average ROE and ROA.
August 09, 2024 | 4:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
WAVE Life Sciences has received mixed ratings from analysts, with an average 12-month price target of $14.25. Financial indicators show challenges, including a decline in revenue growth and negative net margin.
The mixed analyst ratings and the decline in the average price target suggest a neutral short-term impact on WVE's stock price. Financial challenges such as declining revenue growth and negative net margin further support a cautious outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100